13F Pro quality score
Rank #2,528 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Vivos Therapeutics, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $17.4M | $-21.2M | -114.1% |
| FY 2024 | 10-K | $15.0M | $-11.1M | -74.3% |
| FY 2023 | 10-K/A | $13.8M | $-13.6M | -125.3% |
| FY 2022 | 10-K/A | $16.0M | $-23.8M | -156.2% |
| FY 2021 | 10-K | $16.9M | $-20.3M | -120.7% |
| FY 2020 | 10-K | $13.1M | $-12.1M | -92.2% |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Vivos Therapeutics, Inc. (VVOS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VVOS at 28.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,528 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Vivos Therapeutics, Inc. reports quarterly revenue of $5.2M, net income of $-5.5M, an operating margin of -93.6%. Top institutional holders of VVOS by reported 13-F value include GEODE CAPITAL MANAGEMENT, IHT Wealth Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VVOS trades on the Nasdaq exchange and files with the SEC under CIK 1716166. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VVOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vivos Therapeutics, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1716166 →